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A regression model for per capita public pharmaceutical expenditure is analyzed. The necessity of simultaneously 
controlling for dynamic patterns and spatial spillover in such analyses is demonstrated. In contrast to previous studies of 
impact of small-area variation, the present study exploits important aspects related to spatial dynamics as the effects of 
spatial spillover are analyzed and interpreted within a framework of spatial dynamics and spatial error-correction. It is 
shown that such dynamics bear important implications related to spatial convergence of a pharmaceutical market.  The 
paper is accessible to an audience experienced with linear regression; basic exposure to spatial statistics is helpful but 
not strictly necessary. 
 
 
 
Introduction 
 
During the last decade, public pharmaceutical 
expenditures in Spain have grown at a rate superior to 
the total public health care expenditure (DARBÁ, 
2003a, DARBÁ, 2003b). Thus, public pharmaceutical 
expenditures make up an increasing proportion of total 
public health care expenditures. Indeed, pharmaceutical 
expenditures made up 16.8% in 1991 and had in 2002 
increased to make up 23% of total health care 
expenditures (LOPEZ-CASASNOVAS et al., 2005). This 
growth is found not only in Spain, but is a general feature 
of European Union countries (ESS et al., 2003); however, 
Spanish pharmaceutical expenditures as a share of public 
health care expenditures exceed EU averages (LOPEZ-
CASASNOVAS, 2005). It is thus crucial to analyze the 
causes of this growth differential in order to focus on a 
rational use of medicine. 
The regulation of the pharmaceutical market in Spain is 
shared between national regulatory bodies and regional 
authorities. There are notable differences in health 
resources supply and health care expenditure across 
regions (LOPEZ-CASASNOVAS et al., 2005) and there 
is evidence of regional variation in prescription rates and 
expenditure per prescription resulting in regional 
heterogeneity in pharmaceutical expenditures, and in 
pharmaceutical expenditures as a share of total regional 
health care expenditures (COSTA-FONT and PUIG-
JUNOY, 2004). 
 
Studies on pharmaceutical expenditures from a regional 
perspective are very scant, although it is possible to find 
a few articles dealing with the analysis of regional health 
care expenditures (see e.g. KITCHENER et al., 2003, 
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LEVAGGI and ZANOLA, 2003, LOPEZ-
CASASNOVAS and SAEZ, 2001, MOSCONE and 
KNAPP, 2005). Despite the ample body of evidence of 
geographical differences in the use of health-care 
procedures in the literature on small-area variation in 
health care (FOLLAND et al., 2003, HAM, 1988, 
JOINES et al., 2003, WENNBERG and GITTELSOHN, 
1973, WESTERT et al., 2004), few studies have 
examined the geographical variability in the use of 
pharmaceuticals (see e.g. DUBOIS et al., 2002, METGE 
et al., 1999, MORGAN, 2005). The causes of variation 
discussed in the literature are the prevalence of diseases, 
mixed opinions about the effectiveness of surgery, 
practice style, health supply resources and differing 
patient preferences. 
 
Only a few studies of small-area variations have 
considered spatial variation in medical practice. 
WESTERT et al. (2004) studied spatial disparities in 
hospital discharges (as measured by coefficients of 
variations) and found these disparities to be 
approximately unchanged during the 1980s and 1990s. 
JOINES et al. (2003) found that hospitalization rates for 
low back problems varied significantly across the 
counties of North Carolina. They further found that 
counties with similar rates clustered geographically and 
concluded that spatial effects are important and should 
be considered in small area studies. MOSCONE and 
KNAPP (2005) explored the spatial patterns of mental 
health expenditure and established – as in Joines et al. – 
the importance of controlling for spatial spillover. 
Moscone and Knapp’s study found a positive significant 
spatial effect suggesting that adjacent local authorities 
mimic the behavior of their neighbours and tend to have 
similar mental health expenditure. In contrast to the 
present study, however, none of the two latter studies 
incorporated dynamic properties as a part of their 
analysis. 
 
The present study will focus on the regional variations in 
the models of public pharmaceutical expenditures in 
Spain, and will thus contribute to the literature on small-
area variation and determinants of health care 
expenditure. The aim of our study is to analyze the 
determinants of provincial-level pharmaceutical 
expenditures in Spain while controlling for spatial 
effects. However, in contrast to the above mentioned 
small-area studies, we go deeper into the nature of spatial 
spillover and show that this spillover contains valuable 
information regarding the conditional spatial 
convergence of expenditure models. 
 
In the case of Spain, large provincial variations in models 
of public pharmaceutical expenditures are to be 
expected. It is thus important to analyze not only the 
effects of change over time in the determinants on the 
expenditures, but also the effects of inter-provincial 
differences in determinants on inter-provincial 
differences in expenditures. Both targets are achieved by 
using pooled cross-sectional data in the analyses to 
follow. 
  
In order to obtain efficient results, a Seemingly 
Unrelated Regression (SUR) framework is advocated. 
The SUR is specifically designed to capture inter-
temporal residual correlation and time-varying residual 
variances, and is favored over the simpler but less 
efficient OLS framework. We show that the SUR 
framework leads to a global (i.e., non-spatial) 
specification. Potential spatial spillover effects are 
modeled to provide a local (i.e., adjusted for spatial 
dynamics) specification. Deeper analyses of the spatial 
dynamics are obtained by applying a spatial speed of 
adjustment re-specification and spatial error-correction 
specifications. It is concluded that spatial convergence of 
expenditure behavior is present, but that the speed of 
this convergence is relatively slow, due to a large 
endogenous spillover expressing rigidities which are 
caused by supra-provincial forces such as regulation 
and/or market imperfection. 
 
The Spanish pharmaceutical market 
 
In Spain, the prices of publicly financed pharmaceuticals 
are fully or partially controlled, and the price index of 
medicine has practically not risen in the last decade. 
Nevertheless, this does not preclude the fact that new 
products entering the market are introduced at a sales 
price higher than that of the already existing ones. 
Several studies have shown that the replacement of older 
drugs by newer, more expensive drugs is the single most 
important reason for the increase in pharmaceutical 
expenditures (see e.g. DUBOIS et al., 2000, 
GERDTHAM and LUNDIN, 2004, MORGAN, 2005), 
whereas the real price index of existing drugs is 
decreasing. The second most important reason is that a 
larger quantity is consumed because of increases in the 
intensity of medication in terms of defined daily doses 
per patient. Similar results are found in analyses of the 
increase in pharmaceutical expenditures in Spain 
(DARBÁ, 2003b, ROVIRA et al., 2001). 
 
The Spanish national health system is a decentralized 
system in which the regulation of the pharmaceutical 
market is shared between national regulatory bodies and 
the regional authorities – called Autonomous 
Communities (AC) - however, most of the key 
regulatory bodies are run centrally at the national level 
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to reduce diversity and maintain overall control 
(COSTA-FONT and PUIG-JUNOY, 2004); see Figure 1 
for a map of provinces by AC.  
 
 
Figure 1. Provinces by Autonomous Communities 
 
Even though cost containment has been a major priority 
for publicly financed pharmaceuticals this has not 
resulted in significant savings in public expenditures 
(COSTA-FONT and PUIG-JUNOY, 2004, DARBÁ, 
2003a, DARBÁ, 2003b). The average price for 
pharmaceuticals is below EU averages with older drugs 
priced significantly below the EU average (PUIG-
JUNOY, 2004). The market for generic drugs was small 
compared to the EU average, accounting for 3% of total 
drug sales in 2000 and had increased to 6.4% of total 
drug sales by 2003 (COSTA-FONT and PUIG-JUNOY, 
2004). There seems to be significant regional 
heterogeneity in the use of generics (COSTA-FONT 
and PUIG-JUNOY, 2004). New drugs are not priced 
significantly below the EU average and these drugs 
account for the largest market share (COSTA-FONT 
and PUIG-JUNOY, 2004, DARBÁ, 2003a, DARBÁ, 
2003b).  
 
Different cost containment policies such as negative lists 
of excluded drugs, the regulation of profits, repayments 
from pharmaceutical companies, the reference pricing 
system and the promotion of the use of generic drugs 
have had little effect on the overall increase in 
pharmaceutical expenditures. Some of these policies are 
under the devolved responsibility of the 17 regional 
health systems. The ACs have gradually become 
significant actors in the pharmaceutical policy along with 
the decentralization process starting in the early 1980s 
until the completion of the devolution process in 2002. 
 
Funding is mainly centrally collected and distributed to 
the ACs. Until 2001, regional health care financing was 
decided in a separate negotiation between the Minister 
of Health and the corresponding Regional Ministers in 
the 17 ACs, mainly allocating funds as block grants 
following the lines of an unadjusted capitation formula 
(LOPEZ-CASASNOVAS et al., 2005). Since 2002 the 
health care expenditures have been allocated as part of 
general financing using a capitation formula with some 
demographic adjustments. Health care expenditures 
account for around 40% of the ACs’ total funding. The 
ACs have some possibilities of raising funding by levying 
higher taxes; however, various central funds strive to 
maintain territorial equity. 
 
There are some inter-regional inequalities in health 
expenditure per capita but the coefficient of variation in 
regional health care expenditure per capita is one of the 
lowest among health care systems for which territorial 
health care expenditures may be identified (see LOPEZ-
CASASNOVAS and SAEZ, 2001). There seems to be 
significant differences in hospital specialization, 
physician density and technology and it has been 
suggested that this diversity can be partly explained by 
differences in particular GDP and population structures 
(LOPEZ-CASASNOVAS et al., 2005). The regional 
inequality in health expenditure is however not 
correlated with inequality in health outcomes (LOPEZ-
CASASNOVAS et al., 2005). 
 
Modeling spatial dynamics  
 
The point of departure is a linear regression model. 
Assuming initially one cross-section of N observations, 
this reads as 
,00 ttNt Xiy υ+β+α= ),0(~ 2 IN ttt συ    (1) 
where Xt is an N by K dimensional matrix of explanatory 
variables, yt an N dimensional vector of endogenous 
observations, 0β  a K dimensional coefficient vector, 0α   
a constant term,  a column vector of N ones, and  a 
residual with variance . Applying pooled data for T 
periods leads to T equations, one for each time period. 
The residuals of the T equations are correlated, and the 
variances for the cross-sections vary over time. Between 
any two time periods, the residual covariance reads as 
Ni tυ
2
ttσ
' 2( )t s tsE Iυυ σ= ,     Tst ,..,1, = .   (2) 
 
 
- 83 - Spatial dynamics of public pharmaceutical expenditure / Lauridsen et al. 
 
 
 
The model defined by (1)-(2) is estimated efficiently by 
applying Feasible Generalised Least Squares (F-GLS) 
estimation to obtain the ZELLNER (1962) Seemingly 
Unrelated Regression (SUR) estimate for , denoted 
. Further,  is allowed to vary with time by 
extending Xt of formula (1) with interactions between Xt 
and a time trend. 
0β
SUR
0β 0β
 
In terms of spatial econometrics, (1) expresses the 
relationship as a global equilibrium between non-spatial 
variables, i.e.β measures the effects of the exogenous 
variables (X) on public pharmaceutical expenditures (y) 
assuming a global equilibrium to be present, so that 
variations in expenditure across regions are only caused 
by variations in exogenous determinants. For the case of 
conditional convergence, regional adjustment towards 
the global equilibrium is expected to take place. In 
contrast, when convergence is missing, local 
discrepancies will tend to persist. Thus, we have to 
investigate what kind of spatial dynamics is driving the 
economy.  
 
Local developments may spread out at first in the 
neighboring provinces before diffusing over the entire 
economy. Observed spatial spillover may confirm a 
marked spatial dimension of the provincial adjustment 
processes. It may be attributed to rigidity barriers such as 
governmental or provincial regulations, supplier and 
demander mimicking behavior or imperfections of the 
pharmaceutical market. Not only the spatially lagged 
values of the dependent variable, but also those of the 
exogenous variables generally have to be taken into 
account during the transition. Thus, a local model can 
be established of the SAR-SDL (Spatial Autoregressive-
Spatially Distributed Lag; ANSELIN, 1988; FLORAX, 
1992) form (omitting throughout the t subscript for ease 
of notation); 
,1010 ν+β+β+α+α= WXXWyiy N   (3) 
where is the first-order direct (intra-provincial) effect 
of X, while  measures the first-order exogenous spatial 
spillover caused by spatial lags of X. The coefficient 
measures the first-order endogenous spatial spillover, 
while W is an N by N matrix defined so that wij equals 1 
if provinces i and j are neighbors (i≠j) and 0 otherwise. 
By dividing each element in W by the number of non-
zero elements in the row it belongs to, the product Wy  is 
conveniently understood as a variable which, for each 
province, holds the average of y in the neighboring 
provinces. It is important to understand that ,
0β
1β
1α
0β 1β  and 
 measure only the first-order effects caused by X, WX 
and y respectively, but not the full aggregated effects. 
Calculations of the latter are considerably more involved 
because of the presence of contemporaneous spillover. 
Informally spoken, region i spills over into region j, 
which in turn spills over into region i, including a part of 
the spillover received from there. A formal treatment of 
this contemporaneous aggregate spillover and the way it 
forms the aggregate effects is technically involved and 
not strictly needed to understand the presentation; we 
refer to the Appendix for a detailed treatment. 
1α
 
An alternative view of the distinction between the global 
model (1) and the local model (3) is easily obtained by 
rewriting the latter as a ‘speed of spatial adjustment’ 
specification (KOSFELD and LAURIDSEN, 2004): 
ε+θΔ+Δθ+κ+κ= 1010 XyXiy N ,  (4) 
with 
1
0
0 1 α−
α=κ , 
1
10
1 1 α−
β+β=κ , 
1
1
0 1 α−
α−=θ , 
1
1
1 1 α−
β−=θ , and 
11 α−
ν=ε , where WIN −=Δ  is a 
spatial difference operator, so that the product yΔ  
returns a new variable measuring the discrepancy of y 
between a region and the surrounding regions. 
Comparison of (3) to (1) thus shows that the larger the 
values of 1β  and 1α  are, the larger the discrepancy will 
be between the local and the global model. Furthermore, 
Equation (4) shows that if  equals 1, then regional 
discrepancies will persist and not fade out throughout 
the spatial structure. Thus, can be interpreted as a 
spatial speed of adjustment parameter: the larger is, 
the slower the adjustment, and vice versa for a small 
1α
1α
1α
1α . 
Model (4) is equivalent to the spatial Bewley (SBE) 
specification established by LAURIDSEN (2006). 
 
The spatial adjustment may be instructively interpreted 
in terms of spatial error-correction. Some easy 
manipulations of (3) provide alternative representations 
(LAURIDSEN, 2006): 
,)(
)1(
10
010
νββ
βαα
+++
Δ+−+=Δ
WX
XWyiy N    (5) 
,))1((
)1(
110
0
*
10
ναββ
βαα
+−+++
Δ+−+=Δ
K
N
iWX
XWyiy
  (6a) 
,
))(1(
0
110
νβ
καα
+Δ+
−−+=Δ
X
WXWyiy N   (6b) 
where . KXiyy −=*
 
Forms (5) and (6) are algebraically equivalent to (3) and 
(4), but provide different interpretations. Equation (5) is 
a spatial Baardsen specification (SBA), while models 
(6a) and (6b) are variants of a spatial error-correction 
(SEC) model (LAURIDSEN, 2006). In contrast to the 
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SAR-SDL, the SBA and the SEC describe the formation 
of expected local differences in y as depending on local 
differences in X and locally lagged values of X. They are 
distinctive in that the SBA introduces locally lagged 
levels in y, whereas the SEC introduces the locally lagged 
discrepancy between y and X. Thus, in the SEC the term 
( -1) represents the local adjustment to any 
discrepancy. 
1α
 
To improve efficiency, and to adjust for temporal 
dynamics, data from several time periods should be 
applied to these spatial specifications if available. This is 
done by simply implementing (2) to the residuals of (3)-
(6) so that SUR versions of these are obtained. As none 
of the forms (3)-(6) can be estimated consistently using 
Zellner’s F-GLS method because of the 
contemporaneous y values of Wy, we apply a maximum 
likelihood procedure to obtain the coefficients of the 
SAR-SDL-SUR. From these, the parameters of (4)-(6) 
are straightforwardly calculated, and their standard 
errors obtained by applying the Delta method (GREENE, 
2003) to the covariances of the SAR-SDL-SUR. 
 
Data 
 
Data for 50 Spanish provinces (excluding the 
autonomous cities of Ceuta and Melilla) were collected 
and are provided with this paper. These provinces 
correspond with the NUT-3 level of aggregation 
according to EUROSTAT. The provinces are assembled 
in 17 Autonomous Communities (AC). The ACs 
correspond with the NUT-2 level of aggregation 
according to EUROSTAT and they present a higher 
degree of heterogeneity than the provinces. Regarding 
the decentralisation process, 7 of the ACs got 
independent responsibilities during the 1980s and 1990s 
(Cataluña 1981, Andalucía 1984, Comunidad 
Valenciana y País Vasco 1987, Galicia y Navarra 1991, 
and Canarias 1994), while the last 10 got responsibility 
for health care regulation in 2002. Until then these 10 
ACs were centrally regulated.  
 
The data were collected annually from 1996 to 2003 
from two sources, the National Statistical Institute (INE) 
and the Ministry of Health and Consumption (MSC). 
The dependent variable is Public Pharmaceutical 
Expenditure (EXP) per capita. This variable includes 
expenditures on extra-hospital drugs managed by the 
administration, but does not take private purchases into 
account. To capture  the influence of wealth, Gross 
Domestic Product per capita (GDP) is included as an 
explanatory variable. Further, to capture the influence of 
the health care system, variables on the number of 
pharmacists per 1000 inhabitants (PHARM), the 
number of hospital beds per 1000 inhabitants (BEDS), 
and the number of medical doctors per 1000 inhabitants 
(MED) are included. Finally, to capture the influence of 
the population structure, the proportions of females 
(FEM), foreigners (FOREIGN), people over 65 years 
(OLD), and 0-4 year old children (CHILD) in the 
population are included. Table 1 presents the data used 
in this paper, including means and standard deviations 
(averaged over eight years). 
 
The variables describing the population control for 
socio-demographic risk factors and are considered to be 
proxies for need whereas GDP controls for the ability to 
pay. The variables describing the health care system do 
not solely reflect supply factors but are a result of 
interactions between demand and supply factors. Some 
health care system variables may be considered to be 
substitutes to the utilization of pharmaceuticals while 
others are complementary. A priori, one would expect 
the number of pharmacists to be complementary, 
whereas we have no unambiguous a priori hypothesis for 
hospital beds and medical doctors. 
 
Figure 2 shows the distribution of variables (averaged 
over eight years) by provinces. Spatial patterns are 
predominant, though not of a unique nature. For 
expenditures, a clear indication of spatial spillover is 
seen. Comparing the maps in Figure 2 to the map of  
ACs in Figure 1, this spillover seems to be of an intra- as 
well as a supra-AC nature. Furthermore, there seem to
 
Table 1: Data used in the study 
Variable Description Source Mean Std. D. 
EXP Pharmaceutical Expenditure per capita  MSC, Inst. of Sanitary Information 164.899 31.710 
GDP GDP per capita  INE, National Statistical Inst. 9241.57 1766.14 
PHARM Pharmacists per 1000 inhabitant INE, Social Indicators, 2004 1.206 0.225 
BEDS Hospital beds per 1000 inhabitants MSC, National Hospital Catalogue 0.004 0.001 
MED Medical doctors per 1000 inhabitants INE, Social Indicators, 2004 4.183 0.739 
FEM Population proportion of females INE, National Statistical Inst. 0.506 0.006 
FOREIGN Population proportion of foreigners INE, National Statistical Inst. 0.018 0.019 
OLD Population proportion over 65 years INE, National Statistical Inst. 0.185 0.042 
CHILD Population proportion from 0 to 4 years INE, National Statistical Inst. 0.090 0.016 
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be some tendencies to North/West-South/East contrasts. 
With respect to GDP, medical doctors, hospital beds and, 
to some extent, pharmacists a clear North-South contrast 
is evident. This is also the case for some of the population 
characteristics, especially proportions of elderly, children 
and to some extent females, while foreigners seem to 
cluster especially in the East coast provinces. 
 
Results 
 
The model assumed for pharmaceutical expenditures 
employs a multiplicative Cobb-Douglas specification, 
which is linearized by applying logarithmic transforms to 
the variables. BECH et al. (2006) estimated a similar 
model applying the SUR framework. They found that a 
model with common coefficients across years was 
adequate, as the variation over time of the coefficients 
could be captured by adding interaction variables 
between a time trend and the explanatory variables. 
Table 2 reports the global SUR model (i.e., without 
spatial spillover) and a local SAR-SDL-SUR model  
(adjusted for endogenous and exogenous spillover). 
 
It is first clear that the LR test for the global versus the 
local model strongly rejects the former in favor of the the 
local model, the large coefficient of the endogenous 
spatial lag (W*EXP) clearly supports the assumption that 
provincial pharmaceutical expenditures are not only 
   
Figure 2.  Variables (averaged over eight years) by province 
 
 
Table 2. Global and local SUR models (dependent variable: EXP) 
SUR (global) SAR-SDL-SUR (local) SBE-SUR (speed of spatial adjustment) 
Constant 7.645*** 
(0.570) 
Constant  3.711*** 
(0.079) 
W*EXP  0.659*** 
(0.003) 
Constant  10.90*** 
(2.875) 
ΔEXP -1.937*** 
(0.022) 
GDP 0.033 
(0.034) 
GDP  0.092**  
(0.036) 
W*GDP  0.006    
(0.063) 
GDP  0.289*   
(0.170) 
ΔGDP -0.018    
(0.185) 
PHARM 0.015 
(0.034) 
PHARM  0.046    
(0.030) 
W*PHARM  0.084    
(0.067) 
PHARM  0.384*   
(0.222) 
ΔPHARM -0.247    
(0.199) 
BED 0.005 
(0.016) 
BED -0.016    
(0.013) 
W*BED -0.014    
(0.027) 
BED -0.090    
(0.087) 
ΔBED  0.042    
(0.079) 
MED 0.082** 
(0.037) 
MED  0.096*** 
(0.035) 
W*MED -0.139**  
(0.070) 
MED -0.126    
(0.197) 
ΔMED  0.410**  
(0.206) 
FEM 2.212*** 
(0.628) 
FEM -0.209    
(0.618) 
W*FEM  2.883*** 
(1.014) 
FEM  7.855*** 
(2.910) 
ΔFEM -8.469*** 
(2.981) 
FOR 0.013** 
(0.006) 
FOR  0.005    
(0.005) 
W*FOR -0.006    
(0.010) 
FOR -0.001    
(0.030) 
ΔFOR  0.018    
(0.031) 
OLD 0.231*** 
(0.054) 
OLD  0.138*** 
(0.052) 
W*OLD  0.020    
(0.087) 
OLD  0.465*   
(0.257) 
ΔOLD -0.058    
(0.256) 
CHILD 0.203*** 
(0.043) 
CHILD  0.054    
(0.050) 
W*CHILD  0.119    
(0.082) 
CHILD  0.509**  
(0.221) 
ΔCHILD -0.350    
(0.243) 
T*GDP -0.017*** 
(0.004) 
T*GDP -0.025*** 
(0.005) 
W*T*GDP  0.008    
(0.007) 
T*GDP -0.051*** 
(0.017) 
ΔT*GDP -0.024    
(0.022) 
T*PHARM 0.008* 
(0.005) 
T*PHARM  0.001    
(0.003) 
W*T*PHARM -0.006    
(0.009) 
T*PHARM -0.017    
(0.030) 
ΔT*PHAR
M 
 0.018    
(0.027) 
T*BED 0.001 
(0.003) 
T*BED  0.005**  
(0.002) 
W*T*BED -0.004    
(0.004) 
T*BED  0.003    
(0.014) 
ΔT*BED  0.012    
(0.013) 
T*MED -0.018*** 
(0.005) 
T*MED -0.016*** 
(0.005) 
W*T*MED  0.017*   
(0.009) 
T*MED  0.002    
(0.025) 
ΔT*MED -0.050*   
(0.028) 
T*FEM -0.142*** 
(0.053) 
T*FEM  0.058    
(0.058) 
W*T*FEM -0.284*** 
(0.096) 
T*FEM -0.663*** 
(0.256) 
ΔT*FEM  0.836*** 
(0.284) 
T*FOR 0.001 
(0.001) 
T*FOR -0.001    
(0.001) 
W*T*FOR  0.004**  
(0.001) 
T*FOR  0.006*   
(0.003) 
ΔT*FOR -0.010**  
(0.004) 
T*OLD -0.002 
(0.005) 
T*OLD  0.003    
(0.006) 
W*T*OLD  0.008    
(0.009) 
T*OLD  0.032    
(0.026) 
ΔT*OLD -0.022    
(0.027) 
T*CHILD -0.039*** 
(0.007) 
T*CHILD -0.013    
(0.009) 
W*T*CHILD -0.001    
(0.012) 
T*CHILD -0.041*   
(0.022) 
ΔT*CHILD  0.001    
(0.036) 
LogL = 1367.01 LogL = 1432.01 
AIC = -2626.03 AIC = -2724.02 
LR test of global SUR versus local SAR-SDL-SUR = 130.00*** 
Note. Standard errors in parentheses. Significance indicated at 1% (***), 5% 
(**) and 10% (*) levels.
Table 3. Spatial error-correction representations of the local model (dependent variable: ΔEXP) 
SBA-SUR SEC-SUR (formula 6a) 
Constant  3.711*** 
(0.979) 
W*EXP -0.340*** 
(0.002) 
Constant  3.711*** 
(0.979) 
W*EXP* -0.340*** 
(0.002) 
ΔGDP  0.092**  
(0.036) 
W*GDP  0.098*   
(0.058) 
ΔGDP  0.092**  
(0.036) 
W*GDP -0.248*** 
(0.058) 
ΔPHARM  0.046    
(0.030) 
W*PHARM  0.130*   
(0.075) 
ΔPHARM  0.046    
(0.030) 
W*PHARM -0.209*** 
(0.075) 
ΔBED -0.016    
(0.013) 
W*BED -0.030    
(0.029) 
ΔBED -0.016    
(0.013) 
W*BED -0.371*** 
(0.029) 
ΔMED  0.096*** 
(0.035) 
W*MED -0.043    
(0.067) 
ΔMED  0.096*** 
(0.035) 
W*MED -0.383*** 
(0.067) 
ΔFEM -0.209    
(0.618) 
W*FEM  2.674*** 
(0.990) 
ΔFEM -0.209    
(0.618) 
W*FEM  2.333**  
(0.990) 
ΔFOR  0.005    
(0.005) 
W*FOR -0.001    
(0.010) 
ΔFOR  0.005    
(0.005) 
W*FOR -0.340*** 
(0.010) 
ΔOLD  0.138*** 
(0.052) 
W*OLD  0.158*   
(0.087) 
ΔOLD  0.138*** 
(0.052) 
W*OLD -0.182**  
(0.087) 
ΔCHILD  0.054    
(0.050) 
W*CHILD  0.173**  
(0.075) 
ΔCHILD  0.054    
(0.050) 
W*CHILD -0.166** 
(0.075) 
ΔT*GDP -0.025*** 
(0.005) 
W*T*GDP -0.017*** 
(0.005) 
ΔT*GDP -0.025*** 
(0.005) 
W*T*GDP -0.358*** 
(0.006) 
ΔT*PHARM  0.001    
(0.003) 
W*T*PHARM -0.005    
(0.010) 
ΔT*PHARM  0.001    
(0.003) 
W*T*PHARM -0.346*** 
(0.010) 
ΔT*BED  0.005**  
(0.002) 
W*T*BED  0.001    
(0.005) 
ΔT*BED  0.005**  
(0.002) 
W*T*BED -0.339*** 
(0.005) 
ΔT*MED -0.016*** 
(0.005) 
W*T*MED  0.001    
(0.008) 
ΔT*MED -0.016*** 
(0.005) 
W*T*MED -0.339*** 
(0.009) 
ΔT*FEM  0.058    
(0.058) 
W*T*FEM -0.226*** 
(0.087) 
ΔT*FEM  0.058    
(0.058) 
W*T*FEM -0.566*** 
(0.087) 
ΔT*FOR -0.001    
(0.001) 
W*T*FOR  0.002*   
(0.001) 
ΔT*FOR -0.001    
(0.001) 
W*T*FOR -0.338*** 
(0.002) 
ΔT*OLD  0.003    
(0.006) 
W*T*OLD  0.011    
(0.008) 
ΔT*OLD  0.003    
(0.006) 
W*T*OLD -0.329*** 
(0.009) 
ΔT*CHILD -0.013    
(0.009) 
W*T*CHILD -0.014*   
(0.007) 
ΔT*CHILD -0.013    
(0.009) 
W*T*CHILD -0.354*** 
(0.008) 
Note. Standard errors in parentheses. Significance indicated at 1% (***), 5% (**) and 10% (*) level
determined within provinces, but that important supra- 
provincial forces are in play. These could be attributed to 
governmental and provincial regulation or to the supra-
latter. Looking at the coefficients of the spatial lags of 
provincial nature of the pharmaceutical market caused 
by the presence of pharmaceutical companies of such a 
size that they can partly outperform the regional self-
determination of expenditure. Further, several spatial 
lags of exogenous determinants are significant and thus 
indicate that supra-provincial actors react to supra-
provincial levels of determinants, rather than to intra-
provincial levels exclusively. Further, a comparison of 
the global and the local models clearly shows that the 
direct (i.e., non-spatial) effects of population 
characteristics are overstated by the global model, while 
the effect of GDP seems to be understated. On the other 
hand, the effects of health system characteristics seem to 
be properly estimated by the global model. 
 
A closer look at the speed of spatial adjustment (SBE-
SUR) transform of the local model provides a deeper 
insight into the nature of the spatial adjustment process. 
The large negative coefficient for the local discrepancy of 
expenditure ( EXP) clearly shows that a local excess 
expenditure of a province (i.e., a positive ΔEXP) causes 
a downward adjustment, so that a local convergence of 
expenditure is in play. Likewise, for the exogenous 
determinants, the inversely-signed nature of the direct 
effects and the discrepancy effects indicate the presence 
of local convergence. These exogenous discrepancy 
effects are, however, relatively small and weakly 
significant. To illustrate, the direct effect of GDP is 
0.289. If, however, the GDP of a province exceeds the 
average GDP of the surrounding provinces, then the 
effect is downward adjusted by 0.018 times the 
difference GDP. A somewhat stronger effect is in play 
for the number of pharmacists and the number of 
medical doctors. For the former, the direct effect is 
0.384, while the downward adjustment effect of a 
positive local difference is 0.247 times the discrepancy in 
the number of pharmacists. For the latter, the negative 
direct effect of 0.126 is modified in the case of a positive 
local difference by a positive adjustment effect of 0.410 
times the difference in the number of medical doctors. 
     
Δ
Δ
66.01 =α
34.011 −=−α
Table 3 summarizes the spatial error-correction 
specification, which provides further insight into the 
local dynamics. It is seen that local differences in GDP 
cause local differences in pharmaceutical expenditures. 
Regarding health care system characteristics, it is 
obvious that local differences in the number of medical 
doctors cause local expenditure differences. Turning to 
population characteristics, it is apparent that local 
differences in the proportions of old people cause 
differences in expenditures. In both models in Table 3 
the coefficients are the same (-0.340) for the endogenous 
spatial lag. While it returns simply the spatial lag of the 
dependent variable in the SBA-SUR model, in the SEC-
SUR it embodies spatial error-correction mechanisms. 
The adjustment coefficient (W*EXP*) takes a negative 
sign, which generally indicates the working of the error-
correction mechanism. As an effective spatial error-
correction allows the economy to adjust towards 
equilibrium by fast absorption of a spatial spillover, it is 
straightforwardly linked with the existence of conditional 
convergence. However, due to the large endogenous 
spillover (indicated with ) the error-
correction (indicated by , which is 
considerably larger than -1), and thus the speed of 
absorption of the spatial spillover, is relatively slow. 
Thus, important rigidities are demonstrated which slow 
down the opportunities for convergence.  
 
Conclusions 
 
The present study analyzes models of public 
pharmaceutical expenditures and adds to previous 
knowledge regarding not only the necessity but also the 
involved implications of adjusting for spatial spillover 
effects. The importance of interpreting spatial spillovers 
within a spatially dynamic error-correction framework is 
demonstrated. Specifically, it is found that opportunities 
for convergence are slowed down, as the speed of 
absorption of spatial spillovers is considerably slow. This 
in turn is especially due to the presence of a large 
endogenous spatial spillover, presumably caused by the 
complex supra-provincial nature of the pharmaceutical 
market. Thus, the complexity of spatial spillover is 
clearly illustrated, and the need for further evidence on 
the implications and the nature of spatial spillover is 
demonstrated. 
 
SAS code and data sets are available on the CS-BIGS 
web site. 
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Appendix1 
 
The distinction between first-order and aggregate spatial 
spillover was informally touched upon in the treatment 
of the SAR-SDL model (3). The following is devoted to 
a formal treatment of this distinction. Specifically, with 
K explanatory variables, the data generating process for 
the SAR-SDL can be written as 
∑
=
ε++= K
k
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as k indexes variable k in the model, so that xk is the kth 
explanatory variable, i.e., the kth column of X. 
 
To illustrate the role of , consider the expansion of 
the data generating process equation as: 
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1 The authors are indebted to an anonymous referee, who  
provided a substantial part of the derivations in this Appendix. 
 
 
from which it is clear that the aggregate effect of xjk on yi 
is given by 
ijk
jk
i WS
x
y
)(=∂
∂ . 
Especially, it follows further that the aggregate effect of 
xik on yi is given by 
iik
ik
i WS
x
y
)(=∂
∂ . 
Thus, the aggregate spatial spillover effect as well as the 
aggregate non-spatial effect of xk is a complex function, 
capturing the first-order effects as given by 0β  and 1β  as 
well as connectivity/feed back loop influences. Feed back 
loop influences arise from impacts passing through 
neighbors, and back to the observation itself. These will 
vary by the location of the observation and the 
connectivity among observations governed by the spatial 
weight matrix W. 
 
